Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A project using drama that engages with village communities in Cambodia, led by Professor Phaik Yeong Cheah of the Mahidol Oxford Tropical Medicine Research Unit and Nuffield Department of Medicine, has won a Project award in this year’s Vice-Chancellor’s Public Engagement with Research Awards. The project also won the Vice-Chancellor’s Choice Award for Public Engagement with Research.

The announcement was made at an awards ceremony at Keble College, Oxford, on 10th July hosted by Vice-Chancellor Professor Louise Richardson.

The project is aimed at supporting malaria elimination and raising awareness of malaria research in rural villages.

“Such communities often record lower literacy rates compared with urban areas, so leaflets and posters are unlikely to succeed.” says Professor Phaik Yeong Cheah “This research engagement project used Cambodian drama which involves comedy and music to share the stories and key messages.” 

Drama was as an effective way to engage Cambodian villages, selected due to their high malaria incidence. Each village had a two-day workshop led by the drama team with a free public performance on the third evening. During the workshops local children were given singing and drama training, drawing workshops and education about malaria. Villagers contributed real local stories about malaria which were then integrated into the performance.

This project enabled a further strengthening of relationships with the National Malaria Control Programme and provincial health departments for malaria research and also the local school teachers, shop owners and village malaria workers. They also help to build trust between the research team and the local stakeholders.

The participants benefited from learning about malaria, its prevention and treatment, and the children had the opportunity to learn art and theatre and to perform in public.

"We will remember this our whole lives!" said a participating 14-year-old-girl from Battambang in north western Cambodia.

Professor Alison Woollard, University Academic Champion for Public Engagement with Research says:

“These awards highlight the many ways that Oxford’s researchers engage with the public. This includes informing and empowering people by sharing research findings; working in partnership with communities to shape research and enabling citizens to take part in the research by collecting and analysing data through Citizen Science. These winning projects also demonstrate that excellence in engagement results in a ‘win-win’ for both researchers and publics alike.”

About the awards

The Vice-Chancellor's Public Engagement with Research Awards recognise and reward those at the University who undertake high-quality engagement activities and have contributed to building capacity in this area. The awards are in three categories – Early Career Researcher, Building Capacity and Projects. Entrants can be at any level in their career and activities of any scale are welcome.

Similar stories

Researchers call for access to Ivermectin for young children

MORU Bangkok Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

MORU Bangkok Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

MORU Bangkok

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU Bangkok Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Susie Dunachie awarded flagship NIHR career development award

Awards & Appointments MORU Bangkok

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU Bangkok Research

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.